The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
January 23, 2023
Adagrasib (Krazati) for NSCLC (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Adagrasib (Krazati) for NSCLC (online only)
January 23, 2023 (Issue: 1668)
Adagrasib (Krazati – Mirati Therapeutics), a RAS
GTPase family inhibitor, has received accelerated
approval from the FDA for oral treatment of KRAS
G12C-mutated locally advanced or metastatic non-small
cell lung cancer (NSCLC) in adults who...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.